Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO, Marc Voigt

Jessica Amir
August 26, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients’ tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results…

In this video Marc discusses:

  • (0:40) IMM’s progress: the year that was, and the year ahead
  • (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
  • (2:29) Its unique discovery in immunotherapy – which spells new opportunities
  • (4:02) Key catalysts that could drive share price growth
  • (6:00) Fund managers who bought into IMM recently – and how funds raised will be spent

Weekly Wrap 12 July

Grady Wulff
July 12, 2024

Morning Bell 11 July

Grady Wulff
July 11, 2024

Morning Bell 10 July

Grady Wulff
July 10, 2024

Morning Bell 9 July

Sophia Mavridis
July 9, 2024

Morning Bell 8 July

Grady Wulff
July 8, 2024

Weekly Wrap 5 July

Bell Direct
July 5, 2024

Morning Bell 4 July

Bell Direct
July 4, 2024

Morning Bell 3 July

Bell Direct
July 3, 2024

Morning Bell 2 July

Bell Direct
July 2, 2024

Morning Bell 1 July

Bell Direct
July 1, 2024

Weekly Wrap 28 June

Bell Direct
June 28, 2024

Morning Bell 28 June

Bell Direct
June 28, 2024